15 completed, 3 terminated, 3 unknown, 1 recruiting. 12 Phase 3, 7 Phase 2, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 9, Terminated 2, Unknown 1 |
| Phase 2 | 7 | Completed 6, Recruiting 1 |
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow reslizumab: new trials by email Literature Review of reslizumab trials Research Report on reslizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluctuation Analyses of Asthma Patients With Biologics Use Biological Drug - Asthma | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 48 | 2023-12-01 | 2023-11-01 | |
| Similarities and Differences of Biological Therapies for Severe Asthma. Mepolizumab, Omalizumab, Reslizumab - Asthma | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 600 | 2021-04-07 | 2021-04-27 | |
| Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma Reslizumab - Asthma; Eosinophilic | Phase 4 | Completed | McMaster University | 10 | 2021-02-10 | 2024-01-25 |
| Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists Mepolizumab, Reslizumab, Placebo - Healthy Subjects, Pharmacokinetics | Phase 1 | Completed | Food and Drug Administration (FDA) | 72 | 2020-02-17 | 2024-04-22 |
| Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab Reslizumab - Chronic Rhinosinusitis (Diagnosis), Asthma | Withdrawn | University of Rochester | 2017-11-14 | 2019-11-13 | ||
| Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Reslizumab - Asthma | Phase 2 | Recruiting | National Jewish Health | 10 | 2017-09-12 | 2017-09-14 |
| An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo - Asthma | Phase 4 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 5 | 2017-05-08 | 2021-11-09 |
| Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab Reslizumab - Severe Asthma | Phase 2 | Completed | Sociedad Española de Neumología y Cirugía Torácica | 30 | 2017-04-20 | 2018-05-16 |
| A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma reslizumab - Eosinophils, Asthma | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 391 | 2017-03-10 | 2022-12-14 |
| Effect of Reslizumab in Chronic Rhinosinusitis Reslizumab, Placebo - Sinusitis | Phase 3 | Unknown | Joshua S. Jacobs | 30 | 2016-06-01 | 2018-02-01 |
| Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Reslizumab, Placebo - Severe Persistent Asthma, Eosinophilic Bronchitis | Phase 2 / Phase 3 | Completed | McMaster University | 10 | 2015-10-01 | 2018-04-04 |
| An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils Reslizumab, Placebo, Non-Oral Corticosteroid (non-OCS) Asthma Medication - Asthma, Elevated Blood Eosinophils | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 177 | 2015-09-29 | 2021-11-09 |
| Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils Reslizumab, Placebo - Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 468 | 2015-09-28 | 2021-11-09 |
| Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 511 | 2012-02-01 | 2016-06-27 |
| Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Reslizumab - Eosinophilic Asthma | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 1052 | 2011-06-01 | 2016-06-06 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 489 | 2011-04-01 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 464 | 2011-03-01 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 315 | 2011-02-01 | 2016-06-06 |
| Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Reslizumab, Diethylcarbamazine, Placebo - Loiasis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 31 | 2010-04-01 | 2022-01-27 |
| Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis reslizumab - Eosinophilic Esophagitis | Phase 3 | Completed | Ception Therapeutics | 190 | 2008-07-01 | 2017-03-23 |
Showing 20 of 23. Sign in to see all of them.
Asthma (12) · Pulmonary Eosinophilia (6) · Eosinophilic Esophagitis (2) · Bronchiolitis Obliterans Syndrome (1) · Disease (1) · Eosinophilia (1) · Filariasis (1) · Gastroesophageal Reflux (1) · Hypereosinophilic Syndrome (1) · Loiasis (1) · Nasal Polyps (1) · Rhinitis (1) · Rhinosinusitis (1) · Sinusitis (1)
Teva Branded Pharmaceutical Products R&D, Inc. (9) · Ception Therapeutics (3) · McMaster University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Food and Drug Administration (FDA) (1) · Joshua S. Jacobs (1) · National Jewish Health (1) · Sociedad Española de Neumología y Cirugía Torácica (1) · University of Rochester (1)
United States (18) · Canada (10) · Belgium (6) · France (6) · Hungary (6) · Israel (6) · Poland (6) · Russia (6) · Argentina (5) · Czechia (5) · Germany (5) · Mexico (5) · Spain (5) · Ukraine (5) · Australia (4)
Parameswaran Nair, MD, PhD (2) · Amy D Klion, M.D. (1) · Els Weersink, Dr. (1) · Jennifer Deering, MSN, APNP (1) · Joshua Jacobs, MD (1) · Li-Xing Man, MSc, MD, MPA (1) · Michael Wechsler, MD (1)
PMID 25736990, PMID 28159511, PMID 30193936, PMID 30346831, PMID 30964365, PMID 31262379, PMID 31626990, PMID 32066536, PMID 22206777, PMID 27018175, PMID 27056586, PMID 28915080, PMID 33548468
2015 (2), 2016 (1)